Utilization of the ClearPoint® Neuro Navigation System to be Presented at International Parkinson and Movement Disorder Society Meeting
Minimally Invasive Laser Ablation Technique featured as Late Breaking Abstract
IRVINE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Navigation System will be on exhibit at the 21st International Congress of Parkinson’s and Movement Disorders (MDS) taking place June 4- 8, 2017, in Vancouver, BC, Canada. MDS attendees are invited to visit the MRI Interventions booth (#804) to learn more about the ClearPoint Neuro Navigation System.
On Wednesday, June 7, Dr. Jessica Wilden, Founder of Tri-State Neurosurgery at Willis-Knighton Medical Center (Shreveport, Louisiana) will present a review of her clinical experience entitled, “MRI-guided laser interstitial thermal thalamotomy for medically intractable tremor disorders.”
Dr. Wilden commented, “I have been using the ClearPoint System to place electrodes in my movement disorder patients for nearly four years. We are excited to announce the addition of laser ablation thalamotomy to our MRI-based surgery options for select patients. The ClearPoint System allows our team to plan, target and place the laser catheters with real time MRI visualization, which allows exceptional accuracy through a small incision with minimal hair shaving. In addition to caring deeply about clinical and surgical outcomes, we want the patient experience to be as seamless and easy as possible. Our patients appreciate that they can be asleep throughout the procedure and do not have to wear a metal stereotactic head frame.”
The ClearPoint system allows surgeons to plan, target, and adjust trajectories under real time MRI-guided visualization for placement of electrodes, catheters and biopsy needles. Real time MRI imaging provides the surgeon with current views of the patient’s brain anatomy at the time of surgical planning, device alignment, and navigation of selected device to target, resulting in improved accuracy and reduced risk of brain shift associated with standard imaging techniques. Only ClearPoint Neuro Navigation enables laser ablation procedures to be performed entirely in the MRI suite, eliminating the need to transport the patient mid-procedure from the operating room to the MRI suite.
The International Parkinson and Movement Disorder Society (MDS) is a professional society of over 5,000 clinicians, scientists and other healthcare professionals dedicated to improving the care of patients suffering from Parkinson’s disease, tremor disorders, neurodegenerative and neurodevelopmental syndromes, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control, through education and research.
About MRI Interventions, Inc.
Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the Company’s Quarterly Report on Form 10-Q, both of which have been filed with the Securities and Exchange Commission.
Contact: Wendelin Maners, Vice President Sales and Marketing MRI Interventions, Inc. 949-900-6833 For Investors: Matt Kreps, Darrow Associates Investor Relations (512) 696-6401 mkreps@darrowir.com
Released June 1, 2017